Funding for this research was provided by:
Received: 28 March 2021
Accepted: 26 November 2021
First Online: 7 December 2021
: The animal experiments in this study were approved by the Wistar’s Institutional Animal Care and Use Committee.
: Not applicable.
: Hildegund CJ Ertl is a co-founder and holds equity in Virion Therapeutics and has research sponsored by Virion Therapeutics. Colin Magowan owns equity in Virion Therapeutics and is an inventor on a patent application covering, in part, the material in this paper.